Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
MWN-AI** Summary
Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, is set to present new findings from its randomized Phase 3 trial of aglatimagene besadenovec (CAN-2409) for localized prostate cancer at the upcoming American Urological Association (AUA) 2026 Annual Meeting in Washington D.C., from May 15-18, 2026. The presentation, titled "Extended follow-up shows accumulating benefit for patients treated with CAN-2409 + prodrug in combination with standard of care external beam radiation (EBRT)," will be delivered by Dr. Mark G. Garzotto, a Professor of Urology and Radiation Medicine at Oregon Health & Science University.
Candel's presentation aims to highlight the potential benefits observed in patients with intermediate- to high-risk localized prostate cancer following extended follow-up from the PrTK03 randomized Phase 3 clinical trial. This study has garnered attention as a practice-changing trial in urology, reflecting the growing interest in innovative cancer therapies.
Aglatimagene, derived from Candel’s adenovirus platform, has previously shown promise in other cancers, including non-small cell lung cancer and pancreatic ductal adenocarcinoma, and has received multiple regulatory designations, such as Fast Track and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration. Such designations suggest a significant therapeutic potential, especially for those with difficult-to-treat solid tumors.
As an evolving player in the cancer therapy landscape, Candel continues to leverage its enLIGHTEN™ Discovery Platform to develop novel viral immunotherapies. Investors and industry stakeholders will anticipate insights from this key presentation at the AUA, as it may inform future clinical advancements and regulatory developments in cancer treatment. For further details, interested parties can follow the updates on Candel's official website post-event.
MWN-AI** Analysis
Candel Therapeutics, Inc. (NASDAQ: CADL) is poised for a significant opportunity as it prepares to present new data from its Phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) at the upcoming American Urological Association (AUA) Annual Meeting. This presentation is particularly critical as it follows extended patient follow-up, which may yield insights important for stakeholders and enhance the company's stock valuation.
Given the historical context, the efficacy of CAN-2409 in combination with standard external beam radiation therapy (EBRT) for patients suffering from localized prostate cancer is under close scrutiny. The extended follow-up data may provide compelling evidence of the therapy's long-term benefits, potentially reinforcing its competitive position in a crowded oncology market. Investors should remain alert, as positive outcomes could lead to increased analyst coverage and heightened investor interest, especially in light of previously granted FDA designations including Fast Track and Regenerative Medicine Advanced Therapy Designation.
However, potential investors should also consider the inherent risks outlined by Candel’s forward-looking statements. Clinical data can often diverge from expectations, and there remains uncertainty around Candel’s regulatory journey and financial stability. Investors are advised to monitor developments closely leading up to and following the presentation on May 15, 2026, focusing on market sentiments and analyst ratings.
In terms of market strategy, this may be a prime time for cautious investment in CADL shares ahead of the news cycle, while maintaining a close watch on any subsequent data releases and regulatory approvals. Given the potential for paradigm-shifting implications in localized prostate cancer treatment, a well-considered entry point could yield substantial returns for those willing to embrace the associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company’s phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer.
Presentation Details:
Aglatimagene – Localized Prostate Cancer
- Abstract Title: Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) in men with localized prostate cancer: update from PrTK03 randomized phase 3 clinical trial
- Presentation Type: Plenary
- Presenter: Mark G. Garzotto, M.D., Professor of Urology and Radiation Medicine, Oregon Health & Science University, Chief, Urology Section, Portland VA Medical Center
- Session Title: P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology
- Session Date/Time: Friday, May 15, 2026; 11:30 AM - 11:40 AM ET
- Location: Hall D, Walter E. Washington Convention Center, Washington, D.C.
Full abstracts will be released by AUA on date and time of presentation. Details from the presentation will be available following the event on the Candel website at https://www.candeltx.com/media/.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene or CAN-2409) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
FAQ**
How might the upcoming oral presentation at the AUA 2026 meeting impact investor sentiment towards Candel Therapeutics Inc. (CADL) and its lead candidate, aglatimagene besadenovec, for localized prostate cancer?
What potential market advantages could Candel Therapeutics Inc. (CADL) gain if the results from the phase 3 clinical trial for CAN-2409 demonstrate statistically significant improvements in patient outcomes?
Given the fast track and orphan drug designations, how could Candel Therapeutics Inc. (CADL) leverage these regulatory advantages to enhance its commercial strategy for aglatimagene and other therapies?
How does Candel Therapeutics Inc. (CADL) plan to address risks highlighted in its forward-looking statements, particularly regarding the advancement of its clinical programs and securing regulatory approvals?
**MWN-AI FAQ is based on asking OpenAI questions about Candel Therapeutics Inc. (NASDAQ: CADL).
NASDAQ: CADL
CADL Trading
-3.53% G/L:
$5.06 Last:
398,224 Volume:
$5.08 Open:
